Is Global Health overvalued or undervalued?

As of 18 November 2025, the valuation grade for Global Health has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued based on its high valuation ratios, with a PE ratio of 53.35, an EV to EBITDA of 33.18, and a PEG ratio of 2.35. These figures suggest that the stock is trading at a premium compared to its earnings growth potential.
In comparison to its peers, Global Health's PE ratio is significantly higher than that of Narayana Hrudaya, which stands at 46.82, and Apollo Hospitals, which has a PE ratio of 63.51. This indicates that while Global Health is expensive, it is still relatively more favorable than some of its competitors. The company's recent stock performance has shown a 10.49% return over the past year, which outpaces the Sensex's 9.48% return, reinforcing the notion that while the stock is overvalued, it has still managed to deliver better returns than the broader market.